The fork in the road: injection or surgery?

Both ChondroFiller injection and surgical cartilage repair — microfracture, ACI, or MACI — start from the same qualifying condition: a focal, grade-appropriate cartilage lesion in a knee with stable mechanics and no widespread joint degeneration. That shared precondition matters because patients sometimes arrive having read that ChondroFiller can help where surgery cannot, including bone-on-bone arthritis. The clinical evidence does not support this. Neither option is designed for advanced, generalised osteoarthritis, and a consultant assessment will establish that boundary before any treatment discussion begins.

Once a patient clears that threshold, the decision genuinely forks. It is not simply a matter of preference — consultants weigh objective criteria including defect size, cartilage grade on MRI, joint alignment, age, BMI, and what rehabilitation the patient can realistically commit to. Those factors, rather than any general rule about injections being 'better' or 'worse' than surgery, determine which route is appropriate. The sections that follow work through each criterion in turn.

What ChondroFiller does inside the knee

Once injected under ultrasound guidance, ChondroFiller gel solidifies within three to five minutes, bonding to the cartilage surface and forming a dimensionally stable scaffold inside the defect. The product is entirely acellular — it carries no donor cells — and its role is to create a physical lattice that the body's own progenitor cells can migrate into from the surrounding synovium and subchondral bone. This process is called acellular matrix-induced chondrogenesis: the scaffold does the structural work; the patient's biology does the rest. Over six to twenty-four months, recruited cells mature and progressively deposit new cartilage-like matrix at the repair site.

This is not the same as regrowing cartilage. The injection supports the body's own repair processes, and biological response varies between patients. One structural advantage over microfracture is nonetheless clear: because the subchondral bone is never drilled or breached, its mechanical integrity is fully preserved — a consideration that matters for joint stability and for keeping future treatment options open.

On measured outcomes, manufacturer and clinic cohort data report approximately a 30-point IKDC improvement at twelve months, with 70–85% of appropriately selected patients achieving meaningful symptom relief at three to five years; those figures come from sources with a commercial interest, so treat them as indicative rather than definitive. Peer-reviewed support comes from a 2025 prospective study by Demmer et al. (n=59, PMC12498443), which found significantly better cartilage quality scores at follow-up arthroscopy in scaffold-treated patients versus controls — though that study was conducted in the wrist, and independent knee-specific trial data remain limited.

How consultants decide which path fits

Three clusters of variables shape which path a consultant recommends — and understanding the logic behind them helps explain why two patients with seemingly similar symptoms can be offered very different treatments.

Defect characteristics

Defect size on MRI is the primary branch point. Lesions under approximately 2.5 cm² are generally suited to ChondroFiller injection or, where bone access is already planned, microfracture. Defects of 3–4 cm² or larger typically push toward ACI/MACI or the arthroscopic Liquid Cartilage™ pathway. Some providers describe ChondroFiller injection as carrying no strict defect-size ceiling — but that claim does not remove the need for imaging review before any decision is made; it simply means the threshold is assessed case by case rather than ruled out by a number alone. Alongside size, consultants look at ICRS cartilage grade and, critically, the health of the surrounding cartilage bed. If tissue adjacent to the lesion is significantly degraded, suitability for any focused repair approach — injection or surgical — is reduced.

Mechanical pre-conditions

Joint alignment and stability are assessed before any treatment is agreed. Malalignment places disproportionate load on the repair site, and unless that is corrected first — typically by osteotomy — any cartilage intervention is likely to fail regardless of its biological merits. Similarly, ligament laxity that compromises joint stability must be addressed before repair.

Patient profile

Consultants typically look for patients aged 15–55, though active individuals up to 65 are considered. A BMI under 30 and a realistic commitment to postoperative rehabilitation are standard criteria across all focal repair options — whether injection or surgery. These factors are assessed at consultation and cannot be inferred from imaging alone.

ChondroFiller against its surgical comparators

ChondroFiller vs microfracture

Microfracture addresses small focal defects by deliberately piercing the subchondral bone — typically with an awl or drill — to provoke bleeding and trigger a marrow-cell clot that matures into fibrocartilage. That fibrocartilage is mechanically softer and less durable than native hyaline cartilage, and functional gains commonly plateau and decline from around three to five years post-procedure. The bone disruption is also irreversible: once the subchondral plate is breached, that architecture cannot be restored, which can narrow the options available for any subsequent intervention.

ChondroFiller injection, placed under ultrasound guidance as an outpatient appointment, adds scaffold to the defect surface without entering the bone at all. No theatre admission, no incision, and no subchondral drilling — the bone bed stays mechanically intact throughout.

No randomised controlled trial directly comparing ChondroFiller injection with microfracture in knee patients currently exists in the published literature, and that gap is real. Long-term independent data beyond five years from the injection route also remain sparse.

ChondroFiller vs ACI/MACI

ACI — the only cell-based cartilage therapy available on the NHS, approved in 2017 — follows a two-stage surgical path: an initial biopsy to harvest the patient's own chondrocytes, a laboratory cell-expansion phase, then a second surgical procedure to implant the cultured cells. It is suited to larger defects of approximately 3–4 cm² or more and carries an extended rehabilitation commitment across both stages, with risks including graft complications.

ChondroFiller injection replaces that two-episode surgical sequence with a single 30–45-minute outpatient session. For patients who do not meet NHS criteria for ACI, or who cannot commit to two surgical procedures and the interval between them, the injection pathway offers a structurally distinct alternative — without theatre admission or the delays inherent in cell culture.

Practical differences patients weigh up

Once suitability is established, several practical questions tend to determine which path a patient can realistically pursue.

Invasiveness. ChondroFiller is placed via an ultrasound-guided injection at a clinic appointment — no incision, no anaesthetic, no theatre admission. Surgery, whether microfracture or ACI, requires physical entry into the joint: general or regional anaesthesia, one or more incisions, and a post-operative recovery phase that the injection route simply does not involve. For patients who are medically unsuitable for anaesthetic, have caring responsibilities that make inpatient or theatre-based procedures difficult, or simply prefer a minimally invasive approach, the injection pathway removes several of the barriers that surgery creates.

Recovery and return to activity. There is no post-injection equivalent of a surgical non-weight-bearing period. Some localised swelling, a temporary pain flare, and stiffness in the first few days are the expected responses; these are consistent with findings from Demmer et al. (2025), which recorded no significant difference in complications between treated and control patients. Surgical recovery — particularly following a two-stage ACI pathway — typically spans weeks to months before full weight-bearing and progressive rehabilitation are possible.

Funding. ChondroFiller injection is not available on the NHS, nor is it typically covered by major UK private medical insurers including Bupa and AXA. It is self-funded. As a guide, treatment starts at approximately £3,000 for a single box; larger or multi-compartment defects requiring two or three boxes carry higher costs, which the treating clinic confirms following imaging review — not before. ACI remains the only cell-based cartilage therapy available on the NHS (approved 2017), so patients who meet NHS criteria for ACI face a genuinely different funding calculation.

Combination treatment. For patients with both focal cartilage damage and concurrent synovial inflammation, ChondroFiller can be delivered alongside Arthrosamid in a single appointment. These two products should not be conflated: ChondroFiller is the regenerative scaffold component, acting on the articular cartilage surface; Arthrosamid is a non-regenerative polyacrylamide hydrogel targeting the synovial lining. They act through different mechanisms on anatomically distinct structures — which is precisely why the combination is clinically coherent rather than duplicative.

What the assessment pathway looks like at MSK Doctors

The clinical picture across the preceding sections settles into a practical heuristic: a small, isolated focal defect in a well-aligned knee — in a patient who cannot or does not wish to commit to theatre-based surgery — favours the injection pathway; a larger defect, prior failure of microfracture, or NHS eligibility for ACI shifts the balance toward a surgical route. No rule is absolute, and the consultant's job is to work through those variables for each individual patient rather than apply a protocol.

Reaching that decision starts with an assessment, and no GP referral is needed. At MSK Doctors, the initial consultation reviews clinical history and existing imaging; where MRI clarification is required, onMRI™ AI-assisted analysis can support defect classification before any treatment discussion takes place. From that evidence base, the consultant presents the applicable options — ChondroFiller injection, a combination approach, or onward referral to a surgical pathway — determined by what the imaging and examination show. For patients who are suitable, the injection itself is delivered as an ultrasound-guided outpatient appointment at the Regeneration Hub in Sleaford or Grantham.

Appointments can be booked online without a referral at mskdoctors.com.